TLDR Semaglutide helped 40.4% of children move below the obesity threshold in STEP Young. NVO stock fell 1.92% as Novo Nordisk reported positive STEP Young trial results. STEP Young met its main goal with stronger BMI reductions than placebo at week 68. No new safety concerns eme...
Novo Nordisk A/S (NVO) Stock: Drops as Semaglutide Helps 40% of Children Exit Obesity Classification
其他语言标题
- 한국어노보 노르디스크 A/S (NVO) 주식: 세마글루타이드가 어린이 40%의 비만 분류 탈출을 돕자 하락